Skip to search formSkip to main contentSkip to account menu

Y 20811

Known as: Benzoic acid, 4-(hydroxy(5-(1H-imidazol-1-yl)-2-methylphenyl)methyl)-3,5-dimethyl-, monosodium salt, Y-20811 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (3)

Enzyme InhibitorsFibrinolytic AgentsImidazoles

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
Nitric oxide‐induced Cl− secretion in isolated rat colon is mediated by the release of thromboxane A2
We have shown previously that thromboxane A2 (TXA2), which may be released by the anti‐tumour drug irinotecan and by platelet… 
1993
1993
Effects of a Thromboxane Synthetase Inhibitor, Y‐20811, on Infarct Size, Neutrophil Accumulation, and Arrhythmias After Coronary Artery Occlusion and Reperfusion in Dogs
To examine effects of a new thromboxane synthetase inhibitor, Y-20811, on infarct size, neutrophil accumulation, and arrhythmias… 
1992
1992
Arterial thrombosis model with photochemical reaction in guinea-pig and its property.
1992
1992
Effect of the combination of anticoagulant and thromboxane synthetase inhibitor (Y-20811) or receptor blockade (S-1452) on preventing thrombotic cyclic coronary flow reduction in dogs with coronary…
We examined the hypothesis that combined actions of anticoagulant (heparin) and Y-20811, thromboxane A2 synthetase inhibitor… 
1991
1991
Effect of Y-20811, a long-lasting thromboxane A2 synthetase inhibitor, on antigen-induced airway hyperresponsiveness in guinea pigs.
Effect of Y-20811 on airway hyperresponsiveness was studied in sensitized guinea pigs. Airway hyperresponsiveness to… 
1991
1991
[Effects of Y-20811, a specific thromboxane A2 synthetase inhibitor, on chemical mediator-induced bronchoconstriction in guinea pigs].
We investigated the effects of Y-20811 on chemical mediator-induced bronchoconstriction and the release of chemical mediators… 
1989
1989
Phase I Study of Y‐20811, a New Long‐Acting Thromboxane Synthetase Inhibitor by Oral Administration
The safety, pharmacological action and pharmacokinetics of the thromboxane (TX) synthetase inhibitor Y‐20811, a prospective… 
1989
1989
[Pharmacokinetics of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate (Y-20811), a new thromboxane synthetase inhibitor. II. Pharmacokinetics of intact drug and main…
The pharmacokinetics of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoat e (I-Na) in the beagle dog… 
1989
1989
[Pharmacokinetics of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoate (Y-20811), a new thromboxane synthetase inhibitor. I. Isolation and structure elucidation of urinary…
The urinary metabolites of sodium 4-[alpha-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoat e (Y-20811) in dog were… 
1986
1986
Effects of Y-20811, a long-lasting thromboxane synthetase inhibitor, on thromboxane production and platelet function.
Effects of a new imidazole derivative, sodium 4-[alpha-hydroxy-5-(imidazolyl)-2-methylbenzyl]-3,5-dimethyl benzoate dihydrate (Y… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)